Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.
about
Immune checkpoint inhibitors in clinical trialsUpregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patientsTreating advanced melanoma: current insights and opportunities.Nivolumab in combination with ipilimumab for the treatment of melanoma.Metastatic melanoma cells evade immune detection by silencing STAT1.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.
P2860
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Update on benefit of immunothe ...... anoma: the changing landscape.
@ast
Update on benefit of immunothe ...... anoma: the changing landscape.
@en
Update on benefit of immunothe ...... anoma: the changing landscape.
@nl
type
label
Update on benefit of immunothe ...... anoma: the changing landscape.
@ast
Update on benefit of immunothe ...... anoma: the changing landscape.
@en
Update on benefit of immunothe ...... anoma: the changing landscape.
@nl
prefLabel
Update on benefit of immunothe ...... anoma: the changing landscape.
@ast
Update on benefit of immunothe ...... anoma: the changing landscape.
@en
Update on benefit of immunothe ...... anoma: the changing landscape.
@nl
P2860
P356
P1476
Update on benefit of immunothe ...... anoma: the changing landscape.
@en
P2093
McDermott D
Srivastava N
P2860
P304
P356
10.2147/CMAR.S64979
P407
P577
2014-06-20T00:00:00Z